XML 64 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Balance Sheet Components - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 14, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Schedule of Available-for-sale Securities [Line Items]            
Cash and cash equivalents   $ 120,914,000   $ 120,914,000   $ 155,700,000
Impairment loss   0 $ 0 0 $ 0  
API and bulk drug product price true-up   40,325,000   40,325,000   75,055,000
Accrued litigation settlement   28,500,000   28,500,000    
Restructuring plan, expected reduction to workforce, percentage 32.00%          
Restructuring plan, non-recurring charges   12,606,000 $ 0 12,606,000 $ 0  
Cash payments for restructuring   7,900,000        
Accrued restructuring charges   4,700,000   4,700,000    
Foreign subsidiaries [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Cash and cash equivalents   $ 60,100,000   $ 60,100,000   $ 92,500,000